SCHEMBL21055073

SCHEMBL21055073

Cc1cccc(/C=N/Nc2nc(N3CCOCC3)c3[nH]c(C(=O)NC4CCCCC4)cc3n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIKFYVE Q9Y2I7 10/20 0.62
LMNA P02545 4/20 0.46
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
PIK3CD O00329 3/20 0.40
KMT2A Q03164 1/20 0.39
PIK3CA P42336 2/20 0.39
PIK3CB P42338 2/20 0.39
MTOR P42345 2/20 0.39
CNR2 P34972 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
FES P07332 1/20 0.38
FER P16591 1/20 0.38
TYK2 P29597 1/20 0.38
FRK P42685 1/20 0.38
SYK P43405 1/20 0.38
CAMK1D Q8IU85 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30312463 1.00 PIKFYVE (0.62) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL30312442 0.99 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL21054236 0.99 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL21054505 0.98 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL30312534 0.98 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL21054117 0.95 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL30312384 0.93 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL21055036 0.93 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL21055045 0.93 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD
SCHEMBL30312359 0.93 PIKFYVE (0.63) PIKFYVELMNAMAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11603372-B2 Compounds and therapeutic uses thereof VIOGEN BIOSCIENCES, LLC (US) 2023-03-14 US claimed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US claimed
WO-2019113523-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF BAJJI ASHOK (US) 2019-06-13 WO claimed
US-20240016810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS YUMANITY THERAPEUTICS, INC. 2024-01-18 US disclosed
US-11603372-B2 Compounds and therapeutic uses thereof VIOGEN BIOSCIENCES, LLC (US) 2023-03-14 US disclosed
WO-2021252895-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS YUMANITY THERAPEUTICS, INC. (US) 2021-12-16 WO disclosed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US disclosed
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VIOGEN BIOSCIENCES, LLC 2021-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS TARDBP, PIKFYVE, FUS PIKFYVE 2/4885LMNA 2725/4885MAPT 33/4885
US-11603372-B2 Compounds and therapeutic uses thereof IL15, IL17A, IL2 PIKFYVE 944/4885LMNA 1857/4885MAPT 2341/4885
US-20210122752-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF IL15, IL17A, IL2 PIKFYVE 944/4885LMNA 1857/4885MAPT 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.